2020
Summary and Future Applications of Precision Medicine in Pulmonary, Critical Care, and Sleep Medicine
Gomez J, Kaminski N, Himes B. Summary and Future Applications of Precision Medicine in Pulmonary, Critical Care, and Sleep Medicine. Respiratory Medicine 2020, 417-428. DOI: 10.1007/978-3-030-31507-8_28.Peer-Reviewed Original ResearchCritical careSleep medicinePrecision medicine strategiesNovel biomarker candidatesDisease endotypesClinical studiesDisease pathogenesisHealthcare providersNovel interventionsBiomarker candidatesMedicine strategiesPrecision medicineDrug targetsCareMolecular underpinningsWidespread implementationMedicineEndotypesPulmonaryPathogenesisCohortInitial discoveryBiomarkers
2014
T-RECS: STABLE SELECTION OF DYNAMICALLY FORMED GROUPS OF FEATURES WITH APPLICATION TO PREDICTION OF CLINICAL OUTCOMES
Altman R, Dunker A, Hunter L, Ritchie M, Murray T, Klein T, HUANG G, TSAMARDINOS I, RAGHU V, KAMINSKI N, BENOS P. T-RECS: STABLE SELECTION OF DYNAMICALLY FORMED GROUPS OF FEATURES WITH APPLICATION TO PREDICTION OF CLINICAL OUTCOMES. Biocomputing 2014, 20: 431-42. PMID: 25592602, PMCID: PMC4299881, DOI: 10.1142/9789814644730_0041.Peer-Reviewed Original ResearchConceptsTraditional feature selection methodsFeature selection methodCohort of patientsPersonalized medicine strategiesReal expression dataFeature selectionClassification accuracyCluster selectionBiological datasetsClinical outcomesCluster featuresLung diseaseBreast cancerSelection methodPatient classificationStructured natureMedicine strategiesSurvival dataTarget variablesEfficient selectionCohortStable selectionImportant features
2013
Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression.
Chien JW, Richards TJ, Gibson KF, Zhang Y, Lindell KO, Shao L, Lyman SK, Adamkewicz JI, Smith V, Kaminski N, O'Riordan T. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. European Respiratory Journal 2013, 43: 1430-8. PMID: 24177001, DOI: 10.1183/09031936.00141013.Peer-Reviewed Original ResearchConceptsIPF disease progressionDisease progressionIdiopathic pulmonary fibrosis patientsCarbon monoxide diffusion capacityPulmonary fibrosis patientsDisease progression eventsGAP subjectsIPF studiesPathological stromaVital capacityLOXL2 levelsProgression eventsDiffusion capacityFibrosis patientsSpirometric dataDisease severityPhysiological surrogatesProgressionPatientsRiskMultiple limitationsSubjectsLevelsProteomic analysisCohort
2011
Does Ambient Air Pollution Exposure Modify Longitudinal Disease Outcomes In A Cohort Of Patients With Idiopathic Pulmonary Fibrosis?
Richards T, Kuhlengel T, Choi J, Kaminski N, Bascom R. Does Ambient Air Pollution Exposure Modify Longitudinal Disease Outcomes In A Cohort Of Patients With Idiopathic Pulmonary Fibrosis? 2011, a5433-a5433. DOI: 10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a5433.Peer-Reviewed Original Research